Research > ETFs > ETF / ETP Commentary > 

Global X's CHB ETF and China's Growing Biotech Sector

  • Related Symbols
  • CHB
As China continues to lead the global recovery, one area to keep a close eye on is biotechnology and the Global X China Biotech Innovation ETF (CHB).CHB seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index. CHB gives investors:High Growth Potential: CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.Targeted Exposure: CHB delivers targeted exposure to an emerging theme and industry.ETF Efficiency: In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.Regulatory easements and support from the Chinese government have helped propel China’s biotech industry to  second place in the world after the United States. Biotechnology is specifically named as a Strategic Emerging Industry and prioritized by Beijing’s Made in China 2025 and 13th Five Year Plan initiatives.Despite its recent growth, the industry may soon reach a key inflection point, as substantial research and development efforts begin to yield greater commercial results. China’s biotech industry is estimated to be just one-tenth the size of its U.S. equivalent, but the number of annual biotechnology patents granted in China now exceeds the number in the United States.A Biotech Battle with the United States?As mentioned, China’s biotech industry still plays second fiddle to the U.S. The country is looking to change that refrain over the coming years and become the dominant player in the global biotech industry.Its focus on overtaking the U.S. should feed into more strength for the CHB ETF.“Biotech is such a critical area for technological competition between the U.S. and China because it is transforming fields from medicine to military power,” a Lawfare article noted. “The great advances of the 19th century, like chemical fertilizers, resulted from mastering chemistry. In the 20th century, mastery of physics led to nuclear energy—and, more ominously, nuclear weapons. In the 21st century, biology offers a similar mix of peril and promise.”“Beijing has long envied the United States’s dominant position in biotechnology and spent heavily to overtake it,” the article added. “Biotech has been a priority sector for state investment since the 1980s, and by one estimate Beijing had poured some $100 billion into the sector by 2018.”For more news and information, visit the Thematic Investing Channel.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.